Novel Coronavirus Coding (HERC Recommendations)

The following are the ICD-10-CM codes and procedure codes which may be commonly used for patients with suspected or confirmed COVID-19, along with their placements on the Prioritized List/other HSD files.

These recommendations are from staff of the Health Evidence Review Commission (HERC) and have been updated **January 4, 2023**.

- Placements are from the January 1, 2023 Prioritized List, including errata and changes to incorporate new codes since the original posting.
- In addition, staff recommendations for placement of codes released since 1/1/2023 are shown.

This document and the Prioritized List will continue to be updated based on new evidence and information.

ICD-10-CM codes

Code	Code descriptions	Current Placement ***(Italicized lines are unfunded)***	Notes
B97.29	Other coronavirus as the cause of diseases classified elsewhere	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	To be used as a secondary code
J12.81	Pneumonia due to SARS-associated coronavirus	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
J12.82	Pneumonia due to coronavirus disease 2019	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
J12.89	Other viral pneumonia	304 VIRAL PNEUMONIA	
J20.8	Acute bronchitis due to other specified organisms	460 ACUTE BRONCHITIS AND BRONCHIOLITIS	
J22	Unspecified acute lower respiratory infection	*657 RESPIRATORY CONDITIONS WITH NO OR MINIMALLY EFFECTIVE TREATMENTS OR NO TREATMENT NECESSARY*	
J40	Bronchitis, not specified as acute or chronic	*635 CHRONIC BRONCHITIS*	
J80	Acute respiratory distress syndrome	233 ADULT RESPIRATORY DISTRESS SYNDROME; ACUTE RESPIRATORY FAILURE; RESPIRATORY CONDITIONS DUE TO PHYSICAL AND CHEMICAL AGENTS	
J98.8	Other specified respiratory disorders	*657 RESPIRATORY CONDITIONS WITH NO OR MINIMALLY EFFECTIVE TREATMENTS OR NO TREATMENT NECESSARY*	
M35.81	Multisystem inflammatory syndrome (MIS)	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
R05	Cough	DIAGNOSTIC WORKUP FILE	
R06.02	Shortness of breath	DIAGNOSTIC WORKUP FILE	
R50.9	Fever, unspecified	DIAGNOSTIC WORKUP FILE	
U07.1	COVID-19	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
U09.9	Post COVID-19 condition, unspecified	345 NEUROLOGICAL DYSFUNCTION IN COMMUNICATION CAUSED BY CHRONIC CONDITIONS 399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	Secondary diagnosis (code the specific condition related to COVID-19 first, if known)
Z11.52	Encounter for screening for COVID-19	DIAGNOSTIC WORKUP FILE	

Novel Coronavirus Coding (HERC Recommendations)

Code	Code descriptions	Current Placement *(Italicized lines are unfunded)*	Notes
Z20.822	Contact with and (suspected) exposure to COVID-19	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
Z20.828	Contact with and (suspected) exposure to other viral communicable diseases	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
Z23	Encounter for immunization	PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
Z28.310	Unvaccinated for COVID-19	INFORMATIONAL DIAGNOSES	
Z28.311	Partially vaccinated for COVID-19	INFORMATIONAL DIAGNOSES	
Z28.39	Other under-immunization status (non-COVID vaccines)	INFORMATIONAL DIAGNOSES	
Z86.16	Personal history of COVID-19	INFORMATIONAL DIAGNOSES	

CPT/HCPCS codes

Code	Code descriptions	Current Placement *(Italicized lines are unfunded)*	Notes
86318	Immunoassay for infectious agent antibody, qualitative or semiquantitative, single step method (e.g., reagent strip)	Diagnostic Procedure File	Not specific to COVID
86328	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	Diagnostic Procedure File	
86408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen	Excluded File	
86409	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer	Excluded File	
86413	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative	Diagnostic Procedure File	
86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	Diagnostic Procedure File	
87426	Infectious agent antigen detection by immunoassay technique (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV-2 [COVID-19])	Diagnostic Procedure File	
87428	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B	Diagnostic Procedures File	
87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-	Diagnostic Procedure File	

Novel Coronavirus Coding (HERC Recommendations)

Code	Code descriptions	Current Placement *(Italicized lines are unfunded)*	Notes
	CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique		
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	Diagnostic Procedure File	
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	Diagnostic Procedure File	
87798	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism	Diagnostic Procedure File	
87811	Infectious agent antigen detection by immunoassay with direct optical (i.e., visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	Diagnostic Procedure File	
87913	Infectious agent genotype analysis by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), mutation identification in targeted region(s)	Diagnostic Procedure File	
91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, diluent reconstituted, for intramuscular use	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
91302	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	

Novel Coronavirus Coding (HERC Recommendations)

Code	Code descriptions	Current Placement *(Italicized lines are unfunded)*	Notes
	LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use		
91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
91308	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
91309	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
91310	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
91311	Moderna Covid-19 vaccine administration – children ages 6 months to 5 years	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
91312	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Pfizer-BioNTech bivalent booster for 12 yrs and older	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
91313	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Moderna bivalent booster for 18 yrs and older	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
91314	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Moderna bivalent booster for 6-11 years	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	

Novel Coronavirus Coding (HERC Recommendations)

Code	Code descriptions	Current Placement *(Italicized lines are unfunded)*	Notes
91315	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Pfizer-BioNTech bivalent booster for 5-11 yrs	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
91316	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
91317	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
94640	Pressurized or non-pressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure breathing (IPPB) device	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	HCPCS equivalent code: E0570
99072	Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency as defined by law, due to respiratory-transmitted infectious disease	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
99201-99215, 90832-90853, 90791-90792, Many other codes	Office visits	Covered on most lines Covered for diagnostic purposes regardless of diagnosis Should be covered by telemedicine/phone when billed per payer guidelines. Other visit/valuation/assessment/therapy codes are covered as well when clinical value approximates in person service. See Guideline Note A5	
99281-99285	ER visits	Same as 99201-99215	

Novel Coronavirus Coding (HERC Recommendations)

Code	Code descriptions	Current Placement *(Italicized lines are unfunded)*	Notes
98966-98968, 99441-99443, 99421-99423, 98970-98972, G2061-G2063	Telephone or online assessments/telephone or online evaluation and management services	Covered on most lines Covered for diagnostic purposes regardless of diagnosis Correct code depends on communication medium and provider type	
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19])	Diagnostic Procedures File	
D1708	Pfizer-BioNTech Covid-19 vaccine administration – third dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
D1709	Pfizer-BioNTech Covid-19 vaccine administration – booster dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
D1710	Moderna Covid-19 vaccine administration – third dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
D1711	Moderna Covid-19 vaccine administration – booster dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
D1712	Janssen Covid-19 vaccine administration - booster dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
D1713	Pfizer-BioNTech Covid-19 vaccine administration tris-sucrose pediatric – first dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
D1714	Pfizer-BioNTech Covid-19 vaccine administration tris-sucrose pediatric – second dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
E0570	Nebulizer, with compression	Ancillary Procedures File	CPT equivalent is 94640
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	Ancillary Procedures File	
G2012	Brief communication technology-based service (e.g. virtual check-in) by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related E/M service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion	Similar to telephone codes above This code can be used for services provided by telephone or synchronous audio/video	

Novel Coronavirus Coding (HERC Recommendations)

Code	Code descriptions	Current Placement *(Italicized lines are unfunded)*	Notes
M0201	COVID-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
M0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
M0239	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	EUA authorized through April 16, 2021 only
M0240	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
M0241	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	

Novel Coronavirus Coding (HERC Recommendations)

Code	Code descriptions	Current Placement *(Italicized lines are unfunded)*	Notes
M0243	Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
M0244	Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the COVID-19 public health emergency	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
M0246	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the COVID-19 public health emergency	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
M0248	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
M0249	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
M0250	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
Q0220	Tixagev and cilgav, 300mg	Ancillary Procedures File	
Q0221	Tixagev and cilgav, 600mg	Ancillary Procedures File	
Q0222	Bebtelovimab 175 mg	Ancillary Procedures File	
Q0239	Injection, bamlanivimab-xxxx, 700 mg	Ancillary Procedures File	EUA authorized through April 16, 2021 only
Q0240	Injection, casirivimab and imdevimab, 600 mg	Ancillary Procedures File	
Q0243	Injection, casirivimab and imdevimab, 2400 mg	Ancillary Procedures File	See Q0239
Q0244	Injection, casirivimab and imdevimab, 1200 mg	Ancillary Procedures File	

Novel Coronavirus Coding (HERC Recommendations)

Code	Code descriptions	Current Placement *(Italicized lines are unfunded)*	Notes
Q0245	Injection, bamlanivimab and etesevimab, 2100 mg	Ancillary Procedures File	See Q0239
Q0247	Injection, sotrovimab, 500 mg	Ancillary Procedures File	
Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	Ancillary Procedures File	

Vaccine therapy administration/lab codes

Code	Code descriptions	Current Placement (*Italicized lines are unfunded*)	Notes
U0001	2019 Novel Coronavirus Real Time RT-PCR Diagnostic Test Panel (CDC test)	Diagnostic Procedure File	
U0002	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19) using any technique, multiple types or subtypes (includes all targets).	Diagnostic Procedure File	
U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R	Diagnostic Procedure File	
U0004	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCov (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R	Diagnostic Procedure File	
U0005	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	Diagnostic Procedure File	Add on code for CMS
0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; third dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0004A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike		

Novel Coronavirus Coding (HERC Recommendations)

Code	Code descriptions	Current Placement (*Italicized lines are unfunded*)	Notes
	protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose		
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, diluent reconstituted; first dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, diluent reconstituted; second dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, diluent reconstituted; third dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0021A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0022A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; second dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0041A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0042A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0044A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponinbased adjuvant, preservative free, 5 mcg/0.5 mL dosage; booster dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0051A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	

Novel Coronavirus Coding (HERC Recommendations)

Code	Code descriptions	Current Placement (*Italicized lines are unfunded*)	Notes
0052A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0053A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0054A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0064A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0071A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0072A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0074A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0081A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0082A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0083A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0091A	Moderna Covid-19 vaccine administration – children ages 6-11 – first dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0092A	Moderna Covid-19 vaccine administration – – children ages 6-11 – second dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	

Novel Coronavirus Coding (HERC Recommendations)

Code	Code descriptions	Current Placement (*Italicized lines are unfunded*)	Notes
0093A	Moderna Covid-19 vaccine administration – – children ages 6-11 – third dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0104A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, booster dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0111A	Moderna Covid-19 vaccine administration – children ages 6 months to 5 years – first dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0112A	Moderna Covid-19 vaccine administration – – children ages 6 months to 5 years – second dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0113A	Moderna Covid-19 vaccine administration – – children ages 6 months to 5 years – third dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0124A	Pfizer-BioNTech bivalent booster for 12 yrs and older administration	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0134A	Moderna bivalent booster for 18 yrs and older administration	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0144A	Moderna bivalent booster for 6-11 years administration	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0154A	Pfizer-BioNTech bivalent booster for 5-11 yrs administration	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0164A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0173A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	

HERC's Statement of Intent 6: Telephonic Services During an Outbreak or Epidemic

During an outbreak or epidemic of an infectious disease, reducing administrative barriers (e.g. increasing reimbursement rates) for telephonic evaluation and management services (CPT 99441-99443) and assessment and management services (CPT 98966-98968) is appropriate to ensure access to care while avoiding and preventing unnecessary potential infectious exposure.

HERC's Diagnostic Guideline D27: SARS-COV-2 (COVID-19) Testing

Testing for SARS-CoV-2 (COVID-19) virus RNA or viral antigen is a covered diagnostic service.

Antibody testing for SARS-CoV-2 (COVID-19; CPT 86413, 86328 or 86769) is covered as diagnostic only when such testing meets the following criteria:

A) Testing is done using tests that have FDA Emergency Use Authorization (EUA) or FDA approval; AND
B) Testing is used as part of the diagnostic work up in hospitalized patients of

1) Acute COVID-19 infection in a patient with a previous negative COVID-19 antibody test and a negative COVID-19 RNA or viral antigen test; OR
2) Complications of COVID-19 infection, such as myocarditis, coagulopathy, or multisystem inflammatory syndrome in children (MIS-C) or multisystem inflammatory syndrome in adults (MIS-A).

HERC's Guideline Note 106: Preventive Services (*relevant COVID-19 information is **bolded** below*)

GUIDELINE NOTE 106, PREVENTIVE SERVICES

Lines 3,622

Included on Line 3 are the following preventive services:

A) US Preventive Services Task Force (USPSTF) "A" and "B" Recommendations in effect and issued prior to January 1, 2022.
   1) https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations
      a) Treatment of falls prevention with exercise interventions is included on Line 292.
   2) USPSTF "D" recommendations are not included on this line or any other line of the Prioritized List.

B) American Academy of Pediatrics (AAP) Bright Futures Guidelines:
   1) http://brightfutures.aap.org. Periodicity schedule available at https://downloads.aap.org/AAP/PDF/periodicity_schedule.pdf.
      a) Bright Futures is the periodicity schedule for screening for EPSDT for the Oregon Health Plan.
   2) Screening for lead levels is defined as blood lead level testing and is indicated for Medicaid populations at 12 and 24 months. In addition, blood lead level screening of any child between ages 24 and 72 months with no record of a previous blood lead screening test is indicated.

C) Health Resources and Services Administration (HRSA) Women's Preventive Services-Required Health Plan Coverage Guidelines (revised January 2022). Available at https://www.hrsa.gov/womens-guidelines (retrieved on 7/28/2022).

D) Immunizations as recommended by the Advisory Committee on Immunization Practices (ACIP): http://www.cdc.gov/vaccines/schedules/hcp/index.html or approved for the Oregon Immunization Program: https://public.health.oregon.gov/PreventionWellness/VaccinesImmunization/ImmunizationProviderResources/Documents/DMAPvactable.pdf
   1) **COVID-19 vaccines are intended to be included on this line even if the specific administration code(s) do not yet appear on the line when the vaccine has both 1) FDA approval or FDA emergency use authorization (EUA) and 2) ACIP recommendation.**

Colorectal cancer screening is included on Line 3 for average-risk adults aged 45 to 75, using one of the following screening programs:

A) Colonoscopy every 10 years
B) Flexible sigmoidoscopy every 5 years
C) Fecal immunochemical test (FIT) every year
D) Guaiac-based fecal occult blood test (gFOBT) every year

CT colonography (CPT 74263), FIT-DNA (CPT 81528) and mSEPT9 (HCPCS G0327) are included on Line 502 CONDITIONS FOR WHICH INTERVENTIONS RESULT IN MARGINAL CLINICAL BENEFIT OR LOW COST-EFFECTIVENESS.

Colorectal cancer screening for average-risk adults aged 76 to 85 is covered after informed decision making between patients and clinicians which includes consideration of the patient's overall health, prior screening history, and preferences.

Supervised evidence-based exercise programs for fall prevention for persons aged 65 or older OR younger patients who are at increased risk of falls are included on Line 3 using CPT 98961 or 98962 or HCPCS S9451. HCPCS S9451 is only included on Line 3 for the provision of supervised exercise therapy for fall prevention. Programs should be culturally tailored/culturally appropriate when feasible.

Note: CPT 96110 (Developmental screening (e.g., developmental milestone survey, speech and language delay screen), with scoring and documentation, per standardized instrument) can be billed in addition to other CPT codes, such as evaluation and management (E&M) codes or preventive visit codes.

The development of this guideline note was informed by a HERC coverage guidance. See https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Evidence-based-Reports.aspx